Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TKPHF) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q3 2025 value amounting to 0.49.

  • Takeda Pharmaceutical's Equity Ratio changed N/A to 0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49, marking a year-over-year change of. This contributed to the annual value of 0.49 for FY2025, which is 111.13% up from last year.
  • As of Q3 2025, Takeda Pharmaceutical's Equity Ratio stood at 0.49.
  • In the past 5 years, Takeda Pharmaceutical's Equity Ratio registered a high of 0.49 during Q3 2025, and its lowest value of 0.4 during Q1 2021.
  • For the 5-year period, Takeda Pharmaceutical's Equity Ratio averaged around 0.46, with its median value being 0.46 (2022).
  • As far as peak fluctuations go, Takeda Pharmaceutical's Equity Ratio soared by 1277.56% in 2021, and later surged by 111.13% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Equity Ratio stood at 0.42 in 2021, then rose by 8.93% to 0.46 in 2022, then increased by 3.65% to 0.47 in 2023, then increased by 3.6% to 0.49 in 2024, then increased by 0.35% to 0.49 in 2025.
  • Its Equity Ratio was 0.49 in Q3 2025, compared to 0.49 in Q2 2025 and 0.49 in Q1 2025.